Category: General

World Health Organization Explores International Rescheduling of CBD at Expert Committee Meeting

by Todd | Oct 26, 2017 | General, Medical Cannabis, Pharma & Biotech, Research | 0 comments October 26, 2017 Raul Elizalde to speak before WHO Expert Committee on Drug Dependence review of the psychoactivity of CBD. On November 6th, the World Health Organization’s (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence will begin a 5-day agenda set to determine the potential for harm or dependance of 16 different substances, including cannabidiol (CBD). Medical Marijuana, Inc. subsidiary HempMeds® will have a representative speaking before the committee on the first day regarding CBD. While WHO recognizes the medical use of certain substances is indispensable in the treatment of many conditions and that they should be available to patients for such purposes, the committee is also tasked with determining which substances should be regulated or banned internationally as scheduled drugs. WHO has a part in two of the United Nation’s central drug control conventions – the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic substances. WHO is responsible for conducting the medical, scientific, and public health evaluation of potentially harmful substances to determine the UN’s role in regulating them. This is done through the thirteen member Expert Committee on Drug Dependence (ECDD). The committee is made up of an international panel of experts in the field of drug addiction and abuse. The ECDD evaluates the dependence-producing...

Read More

Study: Retail Cannabis Sales Associated With Fewer Opioid Deaths

SHARE THIS POST Thursday, 19 October 2017 Fort Worth, TX: Retail cannabis distribution in Colorado is associated with a reduction in opioid-related mortality, according to data published online ahead of print in The American Journal of Public Health. A team of investigators from the University of North Texas School of Public Health, the University of Florida, and Emory University compared changes in the prevalence of monthly opioid-related deaths before and after Colorado retailers began selling cannabis to adults. Researchers compared Colorado’s data with trends in neighboring states (that had not implemented any change in marijuana’s legal status), and also sought to control for recent changes in the state’s prescription drug monitoring program. Authors reported a 6.5 percent decrease in monthly opioid deaths following retail cannabis sales. They wrote: “Colorado’s legalization of recreational cannabis sales and use resulted in a 0.7 deaths per month reduction in opioid-related deaths. This reduction represents a reversal of the upward trend in opioid-related deaths in Colorado.” Authors concluded, “Legalization of cannabis in Colorado was associated with short-term reductions in opioid-related deaths.” Their data is consistent with prior studies finding that cannabis access is associated with reductions in prescription drug spending, opioid-related hospitalizations, and opioid-related fatalities. For more information, contact Paul Armentano, NORML Deputy Director, at Full text of the study, “Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015,” appears in The American...

Read More

Cannabis Legislation – HR 3530 Introduced

SHARE THIS POST July 31, 2017 – Representative James Comer (R-KY) has introduced H.R. 3530: To amend the Controlled Substances Act to exclude industrial hemp from the definition of marijuana, and for other purposes. The proposed legislation has 15 cosponsors, including Garland Barr (R-KY), Earl Blumenauer (D-OR), Suzanne Bonamici (D-OR), Steve Cohen (D-TN), Kevin Cramer (R-ND), Peter DeFazio (D-OR), Tulsi Gabbard (D-HI), Bob Goodlatte (R-VA), Morgan Griffith (R-VA), Thomas Massie (R-KY), Ed Pearlmutter (D-CO), Collin Peterson (D-MN), Jared Polis (D-CO), Kurt Schrader (D-OR) and Don Young (R-AK). The bill is assigned to the House Energy and Commerce, and the House Judiciary committees. TroyFlowers Author description...

Read More

Cannabis Legislation – HR 3534 Introduced

SHARE THIS POST July 31, 2017 – Representative Suzan DelBene (D-WA) has introduced H.R. 3534: To make the Controlled Substances Act inapplicable with respect to marijuana in states that have legalized marijuana and have in effect a statewide regulatory regime to protect certain Federal interests, and for other purposes. The proposed legislation has three cosponsors, David Cicilline (D-RI), Steve Cohen (D-TN) and Adam Smith (D-WA), and is assigned to the House Energy and Commerce, as well as the House Judiciary committees. TroyFlowers Author description...

Read More
  • 1
  • 2